The debate continues regarding the benefits and timing of immunotherapy infusions. Non -inferiority of late vs early administration (i-TIMES study). Reassuring for our current clinical practices…@peters_solange #ELCC2026

Day 2 of #ELCC26 @myESMO was a blast! 💥
Great insights at the #ESMOYOC Mentorship Session “From trainee to thoracic oncologist: Building your career roadmap” with @peters_solange and @gerryhanna. Thank you 👏
Stay tuned and follow YOCs in the upcoming session!

A successful starting #ESMOYOC event of #ELCC26 with Vesalius talk for finding the your niche in thoracic oncology by @stephanieplsaw 🇸🇬 @NReguart 🇪🇸 @BenjaminBesseMD 🇫🇷 @DoctorJSpicer 🇨🇦

Excellent insights deserve #YoungOncologists to learn from our international experts 🤩

The #OncoAlert5k 🚨Berlin🇩🇪
HUGE THANKS to all of our Friends
We Are ALL OncoAlert 🌐

@DrVilmaPBarcia
@benjiwal
@vibasilios
@marcoscl
@sevincballi
@SandroCavallero
@Gino_K_In_USC
@MayanaNavarro
@DonjetaZeqa
@LouisaHempel
@CameliaDeak
@CameliaDeak
@CathyEngMD icevic
@LaurenMachos

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @bmassutis @matteolambe @Icro_Meattini

📣 #ESMOAcademy24 kicking off today in Zurich exploring key topics in #medicaloncology, such as methodology and interpretation of clinical trials, standard of care and future perspectives in the main tumour types, pharmacokinetics and drug interactions.

🔗ow.ly/rGi350SZfIv